Omega Therapeutics, Inc.: operating expenses
Operating expenses for Omega Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Omega Therapeutics, Inc. financial histories
What this measure means
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
Exact concept: us-gaap:OperatingExpenses. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2023-12-31. The SEC response was captured on 2026-09-21.
This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2023-01-01 | 2023-12-31 | 103,355,000 | USD | 2024-03-28 | 10-K · 0000950170-24-038094 |
| 2022-01-01 | 2022-12-31 | 104,839,000 | USD | 2024-03-28 | 10-K · 0000950170-24-038094 |
| 2021-01-01 | 2021-12-31 | 66,176,000 | USD | 2023-03-01 | 10-K · 0000950170-23-005328 |
| 2020-01-01 | 2020-12-31 | 28,645,000 | USD | 2022-03-10 | 10-K · 0000950170-22-003350 |
Related financial histories
- Omega Therapeutics, Inc.: total assets
- Omega Therapeutics, Inc.: total liabilities
- Omega Therapeutics, Inc.: stockholders equity
- Omega Therapeutics, Inc.: cash and cash equivalents
- Omega Therapeutics, Inc.: net income or loss
- Omega Therapeutics, Inc.: operating cash flow
- Omega Therapeutics, Inc.: capital expenditure payments
- Omega Therapeutics, Inc.: financing cash flow
- Omega Therapeutics, Inc.: investing cash flow
- Omega Therapeutics, Inc.: retained earnings or deficit
- Omega Therapeutics, Inc.: basic weighted-average shares
- Omega Therapeutics, Inc.: diluted weighted-average shares
- Omega Therapeutics, Inc.: basic earnings per share
- Omega Therapeutics, Inc.: diluted earnings per share
- Omega Therapeutics, Inc.: net property, plant and equipment
- Omega Therapeutics, Inc.: share-based compensation expense
- Omega Therapeutics, Inc.: operating income or loss
- Omega Therapeutics, Inc.: current assets
- Omega Therapeutics, Inc.: current liabilities
- Omega Therapeutics, Inc.: current accounts payable
- Omega Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Omega Therapeutics, Inc. / CIK 0001850838
- Captured
- 2026-09-21T17:32:29.082Z
- SEC response SHA-256
c1a5452a6e18f6d25ec146efc0d3502bc1ca6666bd7303c00392f7815e26e14f
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001850838.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))